Differential Radiosensitizing Potential of Temozolomide in MGMT Promoter Methylated Glioblastoma Multiforme Cell Lines

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 4, 2007, Pages 1246-1253

  van Nifterik, Krista A ^a,b   van den Berg, Jaap ^a   Stalpers, Lukas J A ^b   Lafleur, M Vincent M ^a   Leenstra, Sieger ^b   Slotman, Ben J ^a   Hulsebos, Theo J M ^b   Sminia, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Fractionated irradiation; Human GBM cell lines; MGMT; Radiosensitization; Temozolomide

Indexed keywords

CELL GROWTH; CELL PROLIFERATION; FRACTIONATION; GAMMA RAYS; IRRADIATION; METHYLATION;

FRACTIONATED IRRADIATION; HUMAN GBM CELL LINES; MGMT; RADIOSENSITIZATION; TEMOZOLOMIDE;

ONCOLOGY;

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RADIOSENSITIZING AGENT; TEMOZOLOMIDE;

ARTICLE; CANCER RADIOTHERAPY; CELL LINE; CELL PROLIFERATION; CELL SURFACE; CLINICAL ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; GAMMA IRRADIATION; GLIOBLASTOMA; GROWTH CURVE; HUMAN; HUMAN CELL; METHYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIZATION; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; DACARBAZINE; DNA METHYLATION; DOSE FRACTIONATION; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; NEOPLASM PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35448929133     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.07.2366     Document Type: Article

References (41)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
2. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10 (2004) 1871-1874
3. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
4. Brennand J., and Margison G.P. Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene. Proc Natl Acad Sci U S A 83 (1986) 6292-6296
5. Tisdale M.J. Antitumor imidazotetrazines-XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 36 (1987) 457-462
6. Wedge S.R., Porteus J.K., May B.L., et al. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: A comparative study in vitro. Br J Cancer 73 (1996) 482-490
7. Karran P., Macpherson P., Ceccotti S., et al. O6-methylguanine residues elicit DNA repair synthesis by human cell extracts. J Biol Chem 268 (1993) 15878-15886
8. Ochs K., and Kaina B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 60 (2000) 5815-5824
9. Gerson S.L. MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4 (2004) 296-307
10. Hotta T., Saito Y., Fujita H., et al. O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 21 (1994) 135-140
11. Belanich M., Pastor M., Randall T., et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56 (1996) 783-788
12. Silber J.R., Blank A., Bobola M.S., et al. O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: Frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 5 (1999) 807-814
13. Qian X.C., and Brent T.P. Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res 57 (1997) 3672-3677
14. Watts G.S., Pieper R.O., Costello J.F., et al. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17 (1997) 5612-5619
15. Esteller M., Hamilton S.R., Burger P.C., et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59 (1999) 793-797
16. Paz M.F., Yaya-Tur R., Rojas-Marcos I., et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10 (2004) 4933-4938
17. Donson A.M., Addo-Yobo S.O., Handler M.H., et al. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 48 (2007) 403-407
18. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343 (2000) 1350-1354
19. Chakravarti A., Erkkinen M.G., Nestler U., et al. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. Clin Cancer Res 12 (2006) 4738-4746
20. Hermisson M., Klumpp A., Wick W., et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96 (2006) 766-776
21. van Rijn J., Heimans J.J., van den Berg J., et al. Survival of human glioma cells treated with various combinations of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47 (2000) 779-784
22. Wedge S.R., Porteous J.K., Glaser M.G., et al. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8 (1997) 92-97
23. Gerlach B., Harder A.H., Hulsebos T.J., et al. Radiosensitivity and TP 53, EGFR amplification and LOH10 analysis of primary glioma cell cultures. Strahlenther Onkol 178 (2002) 491-496
24. Kleihues P., Burger P.C., Collins V.P., et al. Glioblastoma. In: Kleihues P., and Cavanee W.K. (Eds). Pathology and genetics, tumours of the nervous system. World Health Organization classification of tumours (2000), IARC Press, Lyon 29-39
25. von Deimling A., Fimmers R., Schmidt M.C., et al. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 59 (2000) 544-558
26. van Nifterik K.A., Elkhuizen P.H., van Andel R.J., et al. Genetic profiling of a distant second glioblastoma multiforme after radiotherapy: Recurrence or second primary tumor?. J Neurosurg 105 (2006) 739-744
27. Nygren A.O., Ameziane N., Duarte H.M., et al. Methylation-specific MLPA (MS-MLPA): Simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 33 (2005) e128
28. Balmforth A.J., Ball S.G., Freshney R.I., et al. D-1 dopaminergic and beta-adrenergic stimulation of adenylate cyclase in a clone derived from the human astrocytoma cell line G-CCM. J Neurochem 47 (1986) 715-719
29. Franken N.A.P., Rodermond H.M., Stap J., et al. Clonogenic assay of cells in vitro. Nature Protocols 1 (2006) 2315-2319
30. van Rijn J., van den Berg J., and Meijer O.W. Proliferation and clonal survival of human lung cancer cells treated with fractionated irradiation in combination with paclitaxel. Int J Radiat Oncol Biol Phys 33 (1995) 635-639
31. Bigner S.H., Humphrey P.A., Wong A.J., et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50 (1990) 8017-8022
32. Pandita A., Aldape K.D., Zadeh G., et al. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39 (2004) 29-36
33. Leenstra S., Oskam N.T., Bijleveld E.H., et al. Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer 79 (1998) 159-165
34. Smith J.S., Tachibana I., Passe S.M., et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93 (2001) 1246-1256
35. Tada K., Shiraishi S., Kamiryo T., et al. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: Correlation with patient age and survival. J Neurosurg 95 (2001) 651-659
36. Terada K., Tamiya T., Daido S., et al. Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas. J Neurooncol 58 (2002) 107-114
37. Wemmert S., Ketter R., Rahnenfuhrer J., et al. Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia 7 (2005) 883-893
38. Roos W.P., Batista L.F., Naumann S.C., et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26 (2007) 186-197
39. Srivenugopal K.S., Shou J., Mullapudi S.R., et al. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin Cancer Res 7 (2001) 1398-1409
40. Gudkov A.V., and Komarova E.A. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3 (2003) 117-129
41. Haas-Kogan D.A., Kogan S.S., Yount G., et al. p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int J Radiat Oncol Biol Phys 43 (1999) 399-403